DeepCure Presents HyperCure Clinical Results at 'EuroPCR 2026'

DeepCure announced the results of the first-in-human (FIH) clinical trial for its next-generation hypertension treatment device, "HyperCure," at "EuroPCR 2026," the world’s most prestigious interventional cardiovascular conference.

According to DeepCure on May 20, the results announced correspond to the three-month follow-up of the clinical trial, with 70% of participating patients achieving the target blood pressure of below 140 mmHg. This figure exceeds that of intravascular renal denervation (RDN) devices previously approved by the U.S. Food and Drug Administration (FDA).

Outstanding safety outcomes were also confirmed. No device-related serious adverse events were reported up to three months after the procedure, and there were no cases of intra- or post-procedural complications, end-stage renal disease (ESRD), or newly diagnosed chronic kidney disease (CKD).

Patients’ medication burden was also significantly reduced. While patients were taking an average of six antihypertensive drugs at baseline, this number decreased to 4.5 drugs at the three-month follow-up.

DeepCure is currently conducting an early feasibility study (EFS) at major academic medical centers in the United States and is in discussions with the U.S. FDA regarding entry into global pivotal clinical trials.

Park Chanho, DeepCure’s co-founder and chairman of the board, stated, “We aim to present a near-curative new treatment option for patients with resistant hypertension, overcoming the limitations of conventional intravascular approaches.”

This content was produced with the assistance of AI translation services.